US Sepsis Diagnostics Market (2024-2029)
The US Sepsis Diagnostics Market was valued at $255.5 Million in 2024 and projected to reach to $367.6 Million by 2029, representing a compound annual growth rate of 7.6%. The US sepsis diagnostics market is poised for sustained growth driven by increasing sepsis incidence, heightened clinical awareness of early detection benefits, and continuous innovation in diagnostic technologies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US Sepsis Diagnostics Market Trends and Insights
- This growth in the US reflects increasing hospital admissions for sepsis, rising awareness of early diagnostic importance, and advancing molecular and immunological testing technologies.
- The US healthcare system's emphasis on reducing sepsis-related mortality and improving patient outcomes drives demand for rapid, accurate diagnostic solutions. In the US, sepsis diagnostics adoption is accelerated by regulatory support, reimbursement improvements, and integration of point-of-care testing in intensive care units.
- The US market benefits from strong healthcare infrastructure, significant R&D investment, and a competitive landscape of established and emerging diagnostic manufacturers.
- Between 2024 and 2029, the US is expected to see expanded use of biomarker-based assays, multiplex PCR platforms, and automated blood culture systems across hospitals and clinical laboratories..
Key Market Statistics
- CAGR (2024-2029) 7.6% CAGR
- Market Size, 2024 ~USD 255.5 Million
- Forecast, 2029 ~USD 367.6 Million
- Country US
US Sepsis Diagnostics Market Overview
Market Size & Growth :
The US sepsis diagnostics market is valued at $255.5 million in 2024 and is projected to reach $367.6 million by 2029, representing a robust CAGR of 7.6% over the forecast period.
Rising Hospital Sepsis Cases :
Increasing hospital admissions for sepsis across US healthcare facilities are driving demand for rapid and accurate diagnostic solutions to improve patient outcomes and reduce mortality rates.
Technological Advancement :
Adoption of advanced molecular and immunological testing technologies in US hospitals is accelerating, enabling faster sepsis detection and more precise pathogen identification for targeted treatment.
Healthcare System Focus :
The US healthcare system's emphasis on early diagnosis and infection control protocols is strengthening the adoption of sepsis diagnostic tools across clinical laboratories and intensive care units.
US Sepsis Diagnostics Market Dynamics
- Healthcare providers are investing in rapid molecular testing platforms and biomarker-based assays to reduce time-to-diagnosis and improve patient survival rates.
- Regulatory support and reimbursement policies favoring advanced diagnostics are further accelerating market expansion.
- By 2029, the market is expected to reach $367.6 million as hospitals prioritize sepsis management protocols and integrate next-generation diagnostic solutions into their clinical workflows..
Market Ecosystem
SEPSIS DIAGNOSTICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides integrated sepsis diagnostics solutions across automated blood culture, rapid syndromic molecular testing, microbial identification, and antimicrobial susceptibility testing through platforms used in hospital microbiology laboratories | Enables faster bloodstream infection detection, rapid pathogen identification, improved antimicrobial selection, and stronger antimicrobial stewardship support |
 |
Supports sepsis and bloodstream infection diagnostics through blood culture systems, specimen collection products, microbiology automation, and antimicrobial susceptibility testing solutions used across hospitals and reference laboratories | Improves laboratory workflow efficiency, supports high-volume microbiology testing, reduces turnaround time, and helps clinicians optimize antibiotic therapy |
 |
Through its diagnostics businesses, provides molecular diagnostics, clinical chemistry, immunoassay, and laboratory automation solutions that support infectious disease testing and sepsis-related clinical decision-making | Supports rapid pathogen detection, biomarker-based assessment, automated laboratory workflows, and improved diagnosis of suspected sepsis cases |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Key Takeaways
- The US sepsis diagnostics market is valued at $255.5 million in 2024 and will reach $367.6 million by 2029, growing at 7.6% CAGR.
- The US market is driven by high sepsis incidence rates, regulatory support, and improved reimbursement policies for rapid diagnostic testing.
- Advanced molecular and immunological technologies are gaining adoption across US hospitals and clinical laboratories to enable faster pathogen identification.
- The US competitive landscape includes both established diagnostic manufacturers and innovative startups developing next-generation sepsis detection platforms.
Sepsis Diagnostics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | POINT-OF-CARE TESTS (Test Type) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 7% from 2024 to 2029 |
| Largest Segment | BLOOD CULTURE (Technology) |
| Market Size Base Year (Billions) | ~USD 0.63 (2024) |
| Revenue Forecast (Billions) | ~USD 0.89 (2029) |
| Segments Covered | Technology, Product, Method, Pathogen Type, Type, Test Type, End User |
US Sepsis Diagnostics Market Report Segmentation
7 segment dimensions are covered across the global market.
By Technology
- Biomarkers
- Blood Culture
- Flow Cytometry
- Immunoassays
- Microfluidics
- Molecular Diagnostics
By Product
- Assays & Reagent Kits
- Blood Culture Media
- Instruments
- Software
By Method
- Automated Diagnostics
- Conventional Diagnostics
By Pathogen Type
- Bacterial Sepsis
- Fungal Sepsis
- Other Pathogen Types
By Type
- Dna Sequencing
- Gram-Negative Bacteria
- Gram-Negative Bacterial Sepsis
- Gram-Positive Bacteria
- Gram-Positive Bacterial Sepsis
- Microarrays
- Peptide Nucleic Acid-Fluorescent In Situ Hybridization
- Polymerase Chain Reaction
By Test Type
- Laboratory Tests
- Point-Of-Care Tests
By End User
- Hospitals And Specialty Clinics
- Pathology And Reference Laboratories
- Research Laboratories, Academic Institutes, And Cros
Target Audience
- In Vitro Diagnostics (IVD) Manufacturers : Need detailed US market insights to develop sepsis diagnostic products, assess market entry strategies, and identify opportunities in molecular and immunological testing segments.
- Hospital & Laboratory Administrators : Require market data to justify investments in sepsis diagnostic technologies, benchmark adoption rates, and optimize clinical laboratory capabilities for improved patient outcomes.
- Healthcare Investment Firms : Seek comprehensive US market analysis to evaluate investment opportunities in sepsis diagnostics companies, assess growth potential, and identify acquisition targets.
- Clinical Pathologists & Infectious Disease Specialists : Need market intelligence on emerging diagnostic technologies, clinical adoption trends, and best practices in US healthcare settings for sepsis management.
- Healthcare Consultants & Strategy Advisors : Require US-specific market data to advise healthcare organizations on sepsis diagnostic strategy, technology selection, and competitive positioning in the evolving market.
Key Companies in the US Sepsis Diagnostics Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CEPHEID INC. | United States | Private Company | GeneXpert instruments and Xpert test cartridges,SmartCycler system and associated reagents,Collaborative and specialized assays (e.g., TB, Ebola, USPS BDS), |
| NANOSPHERE, INC | United States | Private Company | Infectious disease molecular assays,Pharmacogenetic and human genetic assays,Protein and ultra-sensitive multiplex assays, |
| TOSOH CORPORATION | Japan | Public Company | Basic chemicals and chlor-alkali (caustic soda, VCM, EDC, sodium bicarbonate),Polymers and petrochemicals (PE, EVA, PVC pastes, synthetic rubber, functional polymers),Advanced materials (battery materials, quartzware, silica glass, thin films, zeolites, zirconia), |
| BIOMÉRIEUX | France | Public Company | Clinical microbiology (ID/AST, blood culture, culture media),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EMAG),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA), |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (syringes, needles, vascular access, sharps, basic disposables),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and related tools),Life Sciences (instruments, genomics, and reagents),Diagnostics (clinical instruments and consumables), |
| T2 BIOSYSTEMS, INC. | United States | Public Company | T2Dx instrument,T2Candida panel,T2Bacteria panel, |
| DIASORIN S.P.A. | Italy | Public Company | Immunodiagnostics – Infectious & Gastrointestinal Diseases, Hepatitis & Retroviruses,Immunodiagnostics – Endocrinology & Metabolic Disorders,Tumor Markers and Oncology Assays, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| BRUKER CORPORATION | United States | Public Company | BSI BioSpin (NMR/EPR and preclinical imaging),BSI CALID (mass spectrometry and molecular diagnostics),BSI Nano (X-ray, AFM, electron microscopy tools), |
| QUIDELORTHO CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care, |
| SYSMEX CORPORATION | Japan | Public Company | Hematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems and reagents,Blood gas, electrolyte, and urinalysis analyzers, |
| ABBOTT LABORATORIES | United States | Public Company | Medical Devices,Diagnostic Products,Nutritional Products, |
| SIEMENS HEALTHINEERS | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| QIAGEN N.V. | Netherlands | Public Company | Sample technology consumables (nucleic acid stabilization/purification),Immune response and infectious disease assays (incl. TB IGRA),Oncology and sexual/reproductive health assays, |
| SEEGENE, INC. | South Korea | Public Company | Respiratory disease detection,Gastrointestinal disease detection,STI and HPV detection, |
| PHC HOLDINGS CORPORATION | Japan | Public Company | Diabetes Management,Healthcare Solutions (EMR, receipt, pharmacy, wellness),Diagnostic and Life Sciences Equipment, |
CEPHEID INC.
Cepheid Inc. is a private molecular diagnostics company founded in 1996 in the United States with 1,700 employees. The company develops and manufactures diagnostic systems and tests.
NANOSPHERE, INC
Nanosphere, Inc. is a private diagnostic company founded in 1998 in the United States with 148 employees. The company focuses on molecular diagnostic technologies.
TOSOH CORPORATION
Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees. The company operates across multiple business segments including diagnostics and healthcare products.
BIOMÉRIEUX
bioMérieux is a French public company founded in 1963 with 14,894 employees. The company specializes in in vitro diagnostics for infectious diseases and industrial microbiology.
BECTON, DICKINSON AND COMPANY
Becton, Dickinson and Company is a United States public company founded in 1897 with 72,000 employees. The company is a global medical technology manufacturer producing diagnostic systems, devices, and reagents.
DANAHER CORPORATION
Danaher Corporation is a United States public company founded in 1969 with 59,000 employees. The company operates a diversified portfolio of businesses including diagnostics and life sciences.
T2 BIOSYSTEMS, INC.
T2 Biosystems, Inc. is a United States public company founded in 2006 with 113 employees. The company develops rapid diagnostic technologies for infectious diseases.
DIASORIN S.P.A.
DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees. The company manufactures and distributes in vitro diagnostic products.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a United States public company founded in 1956 with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and diagnostic solutions.
BRUKER CORPORATION
Bruker Corporation is a United States public company founded in 1960 with 11,085 employees. The company manufactures scientific instruments and analytical systems for research and diagnostics.
QUIDELORTHO CORPORATION
Qiagen N.V. is a Netherlands public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation technologies.
SYSMEX CORPORATION
QuidelOrtho Corporation is a United States public company founded in 1979 with 6,500 employees. The company develops and manufactures rapid diagnostic tests and point-of-care solutions.
ABBOTT LABORATORIES
Sysmex Corporation is a Japanese public company founded in 1968 with 10,861 employees. The company manufactures and sells in vitro diagnostic systems and reagents.
SIEMENS HEALTHINEERS
Siemens Healthineers is a German public company founded in 1896 with 72,369 employees. The company develops and manufactures diagnostic imaging, laboratory diagnostics, and point-of-care testing systems.
QIAGEN N.V.
QIAGEN N.V. is a Netherlands public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation technologies.
SEEGENE, INC.
Seegene, Inc. is a South Korean public company founded in 2000 with 216 employees. The company develops and manufactures molecular diagnostic products and multiplex PCR technologies.
PHC HOLDINGS CORPORATION
PHC Holdings Corporation is a Japanese public company founded in 1948 with 8,647 employees. The company manufactures and sells medical devices and diagnostic equipment.
Reasons to Buy this Report
- Market Size & Forecast Data : Access precise US market valuation ($255.5M in 2024) and 5-year forecasts with detailed CAGR analysis to support strategic planning and investment decisions.
- Growth Driver Analysis : Understand key factors driving the 7.6% CAGR in the US market, including rising sepsis cases, technological adoption, and healthcare system priorities for early diagnosis.
- Competitive Landscape Insights : Identify market opportunities and competitive positioning specific to the US sepsis diagnostics sector, including emerging technologies and clinical adoption patterns.
- Regulatory & Reimbursement Context : Gain insights into US-specific regulatory frameworks, reimbursement policies, and healthcare system dynamics that influence sepsis diagnostic adoption and market growth.
- Strategic Market Intelligence : Leverage US-focused market data to develop targeted go-to-market strategies, identify high-growth segments, and optimize resource allocation for sepsis diagnostic solutions.
Frequently asked questions
What is the current size of the US sepsis diagnostics market?
The US sepsis diagnostics market is valued at $255.5 million in 2024 and is expected to grow to $367.6 million by 2029.
What is the growth rate of the US sepsis diagnostics market?
The US sepsis diagnostics market is growing at a compound annual growth rate (CAGR) of 7.6% from 2024 to 2029.
What factors are driving growth in the US sepsis diagnostics market?
Growth in the US is driven by increasing sepsis incidence, regulatory support, improved reimbursement, technological advances in molecular diagnostics, and hospital emphasis on early detection and patient outcomes.
Which diagnostic technologies are most prevalent in the US market?
The US market features blood culture systems, biomarker-based assays, multiplex PCR platforms, immunological tests, and point-of-care testing solutions integrated into intensive care units.
Who are the key players in the US sepsis diagnostics market?
The US market includes established diagnostic manufacturers, hospital laboratory providers, and emerging biotech companies developing innovative sepsis detection and identification platforms.
RESEARCH METHODOLOGY
This study involved four major activities to estimate the current size of the sepsis diagnostics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study of the global sepsis diagnostics market. The secondary sources used in this study include publications from government and public health organizations such as the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA), European Medicines Agency (EMA), European Centre for Disease Prevention and Control (ECDC), and other regional health authorities. Secondary sources also included corporate and regulatory filings such as annual reports, SEC filings, investor presentations, and financial statements; company websites; product brochures and catalogs; press releases; peer-reviewed journals; clinical guidelines; sepsis-related publications; and infectious disease databases, among others.
These sources provided key information on major players, product portfolios, global product revenues, market classification, sepsis diagnostics technologies, product launches, regulatory approvals, clinical adoption trends, antimicrobial stewardship initiatives, and regional and country-level market developments. Secondary data were collected and analyzed to estimate the size of the global sepsis diagnostics market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, product managers, laboratory directors, infectious disease specialists, microbiologists, pathologists, hospital procurement professionals, consultants, and other stakeholders to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the sepsis diagnostics market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market, including product, technology, method, pathogen type, test type, sample type, complexity, clinical utility/management pathway, end user, and region.
The market size estimate included revenues from blood culture media, assays and reagent kits, instruments, and software used in sepsis diagnostics. It also included technologies such as blood culture/microbiology testing, immunoassays, molecular diagnostics, flow cytometry, mass spectrometry, and clinical chemistry and blood gas analysis. Company revenues, product mapping, installed base, test volumes, average selling prices, adoption rates, disease burden, hospital testing patterns, and regional laboratory infrastructure were analyzed to estimate the market size.
Data Triangulation
After estimating the overall market size through the market size estimation process, the total market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved analyzing various factors and trends from both the demand and supply sides.
On the supply side, company revenues, product portfolios, installed base, product launches, regulatory approvals, geographic presence, and diagnostic platform adoption were analyzed. On the demand side, sepsis incidence, bloodstream infection burden, hospital admissions, ICU testing volumes, laboratory test utilization, antimicrobial stewardship requirements, and adoption of rapid molecular and biomarker-based diagnostics were considered. The final estimates were validated through primary interviews and cross-checked against secondary research.
Market Definition
Sepsis diagnostics refers to in vitro diagnostic products, platforms, and testing solutions used for the early detection, diagnosis, pathogen identification, risk stratification, antimicrobial stewardship support, and prognosis/outcome prediction of sepsis and bloodstream infections. These diagnostics help clinicians identify infection, determine the causative pathogen, assess disease severity, support antimicrobial treatment decisions, and monitor patient condition in emergency departments, ICUs, hospitals, specialty clinics, and diagnostic laboratories. The market includes blood culture media, assays and reagent kits, instruments, and software used across technologies such as blood culture/microbiology testing, immunoassays, molecular diagnostics, flow cytometry, mass spectrometry, and clinical chemistry and blood gas analysis. It also includes laboratory and point-of-care tests used for bacterial, fungal, parasitic, and polymicrobial sepsis, as well as other sepsis-related diagnostic applications.
Key Stakeholders
- Manufacturers and distributors of sepsis diagnostics products
- In vitro diagnostic (IVD) companies
- Blood culture and microbiology testing companies
- Molecular diagnostics companies
- Immunoassay and biomarker testing companies
- Mass spectrometry and microbial identification platform providers
- Clinical chemistry and blood gas analyzer manufacturers
- Point-of-care diagnostics companies
- Hospital laboratories
- Pathology and reference laboratories
- Hospitals and specialty clinics
- Emergency departments and intensive care units
- Infectious disease specialists, microbiologists, and pathologists
- Research laboratories and academic institutes
- Clinical research organizations (CROs)
- Contract research and diagnostic service providers
- Regulatory authorities and government health agencies
- Public health organizations
- Group purchasing organizations and hospital procurement teams
- Diagnostics suppliers and raw material providers
- Market research and consulting firms
- Venture capitalists and investors
Report Objectives
- To define, describe, segment, and forecast the global sepsis diagnostics market, by product, technology, method, pathogen type, test type, sample type, plexity, clinical utility/management pathway, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall sepsis diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to six regions: North America(US and Canada), Europe (Germany, France, the UK, Switzerland, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America), the Middle East [GCC and the Rest of Middle East], and Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, collaborations, expansions, and other developments
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe Sepsis Diagnostics market, by country
- Further breakdown of the Rest of Asia Pacific Sepsis Diagnostics market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Get the Full Sepsis Diagnostics Market Report
Full forecast, segment splits, and company analysis for all Sepsis Diagnostics Market.
- Italy Sepsis Diagnostics Market
- Spain Sepsis Diagnostics Market
- Japan Sepsis Diagnostics Market
- China Sepsis Diagnostics Market
- India Sepsis Diagnostics Market
- Australia Sepsis Diagnostics Market
- South Korea Sepsis Diagnostics Market
- Brazil Sepsis Diagnostics Market
- Mexico Sepsis Diagnostics Market
- Canada Sepsis Diagnostics Market
- Germany Sepsis Diagnostics Market
- UK Sepsis Diagnostics Market
- France Sepsis Diagnostics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
